In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 2.19 below Solana Company average.

Within Medical Equipment & Supplies industry 78 other companies have achieved higher Quick Ratio than Solana in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 718 to 1185.

Explain Quick Ratio?
How much Cash & cash equivalents HSDT�s has?
What are HSDT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

HSDT Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	0 %	-45.26 %	66.11 %	-12.25 %	27.09 %
Y / Y Cash & cash equivalent Change	296.3 %	569.3 %	3477.02 %	-4.84 %	-69.52 %
Quick Ratio MRQ	2.19	3.85	49.92	3.37	0.55
HSDT's Total Ranking	# 1185	# 718	# 43	# 675	# 2115
Seq. Current Liabilities Change	5.98 %	-23.94 %	37.67 %	-9.89 %	-41.99 %
Seq. Cash & cash equivalent Change	-39.65 %	-94.13 %	1940.98 %	448.06 %	1.93 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 79
Healthcare Sector	# 479
Overall Market	# 1185

Quick Ratio Statistics
High	Average	Low
49.92	4.07	0.19
(Sep 30 2025)		(Sep 30 2017)

Financial Statements
Solana's Current Liabilities	$ 2 Millions	Visit HSDT's Balance sheet
Solana's Cash & cash equivalent	$ 4 Millions	Visit HSDT's Balance sheet
Source of HSDT's Sales		Visit HSDT's Sales by Geography

Cumulative Solana's Quick Ratio

HSDT's Quick Ratio for the trailling 12 Months

HSDT Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-9.17 %	-4.65 %	39.07 %	26.05 %	40.46 %
Y / Y Cash & cash equivalent TTM Growth	1076.62 %	850 %	608.57 %	-46.14 %	-49.81 %
Quick Ratio TTM	17.33	16.93	13.58	1.34	1.34
Total Ranking TTM	# 3102	# 2486	# 2522	# 3048	# 2125
Seq. Current Liabilities TTM Growth	0 %	-16.04 %	11.29 %	-2.8 %	4.98 %
Seq. Cash & cash equivalent TTM Growth	2.37 %	4.68 %	1026.85 %	-2.56 %	-17.34 %

Quick ratio ranking by company, industry and sector >> Back to HSDT Financial Strength Comparisons >> Go to Compare HSDT Quick Ratio to its Competitors

On the trailing twelve months basis HSDT Cash & cash equivalent more than doubled by 296.3 % in Q1 2026 year on year, while Current Liabilities rose to $2 millions, this led to increase in in Solana's Quick Ratio to 17.33, above HSDT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 176 other companies have achieved higher Quick Ratio than Solana. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2486 to 3102.

Explain Quick Ratio?
How much Cash & cash equivalents HSDT�s has?
What are HSDT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 177
Healthcare Sector	# 824
Within the Market	# 3102

trailing twelve months Quick Ratio Statistics
High	Average	Low
14.53	3.6	0.44
(Sep 30 2025)		(Jun 30 2018)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Medical Equipment & Supplies Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Mobia Medical Inc	5.72	$ 55.725 Millions	$ 9.750 Millions
Sharps Technology Inc	5.55	$ 12.321 Millions	$ 2.219 Millions
Omada Health Inc	5.38	$ 211.765 Millions	$ 39.327 Millions
Transmedics Group Inc	5.02	$ 461.739 Millions	$ 91.920 Millions
Heartflow Inc	5.00	$ 158.316 Millions	$ 31.636 Millions
Irhythm Holdings Inc	4.96	$ 549.620 Millions	$ 110.901 Millions
Tactile Systems Technology Inc	4.86	$ 74.993 Millions	$ 15.442 Millions
Nutriband Inc	4.81	$ 4.006 Millions	$ 0.832 Millions
Trisalus Life Sciences Inc	4.80	$ 56.553 Millions	$ 11.786 Millions
Profound Medical Corp	4.74	$ 50.295 Millions	$ 10.607 Millions
Sight Sciences Inc	4.68	$ 84.962 Millions	$ 18.163 Millions
Iradimed Corporation	4.65	$ 56.374 Millions	$ 12.118 Millions
Biolife Solutions Inc	4.44	$ 80.996 Millions	$ 18.253 Millions
Soleno Therapeutics Inc	4.40	$ 255.599 Millions	$ 58.049 Millions
Inspiremd Inc	4.40	$ 41.570 Millions	$ 9.443 Millions
Axogen inc	4.25	$ 101.601 Millions	$ 23.898 Millions
Outset Medical Inc	4.17	$ 156.706 Millions	$ 37.607 Millions
Innovative Eyewear Inc	4.14	$ 4.378 Millions	$ 1.059 Millions
Autonomix Medical Inc	4.11	$ 7.004 Millions	$ 1.705 Millions
Fractyl Health Inc	4.10	$ 63.168 Millions	$ 15.408 Millions
Hyperfine Inc	4.02	$ 40.778 Millions	$ 10.154 Millions
Orasure Technologies Inc	4.01	$ 176.964 Millions	$ 44.084 Millions
Kestra Medical Technologies Ltd	3.90	$ 196.434 Millions	$ 50.372 Millions
Procept Biorobotics Corporation	3.86	$ 245.641 Millions	$ 63.636 Millions
Clearpoint Neuro Inc	3.75	$ 35.593 Millions	$ 9.480 Millions
Mimedx Group Inc	3.59	$ 159.773 Millions	$ 44.550 Millions
Aethlon Medical Inc	3.47	$ 5.026 Millions	$ 1.447 Millions
Novocure Limited	3.40	$ 432.004 Millions	$ 127.239 Millions
Nexalin Technology Inc	3.35	$ 2.708 Millions	$ 0.808 Millions
Capsovision Inc	3.34	$ 17.933 Millions	$ 5.363 Millions

Date modified: 2026-08-30T14:52:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.